FDA Grants Approval for Lung Cancer Study

The U.S. Food and Drug Administration (FDA) granted Investigational Device Exemption (IDE) approval for Calypso Medical Technologies, Inc.’s clinical study evaluating real-time tracking of lung cancer tumors during radiation delivery. Investigators in the United States will implant three anchored Beacon® transponders in patients’ lungs and use the Calypso® System to precisely track tumor location and movement during lung cancer radiation therapy.Calypso’s electromagnetic technology is the only non-ionizing guidance solution that uses internal markers to keep the radiation beam precisely focused on the tumor in real-time, without adding unnecessary radiation. Used in prostate cancer radiation therapy, the Calypso System has been used to treat more than 10,000 patients worldwide.Learn more from Calypso.